Bioasis Technologies (TSX.V: BTI) (OTCQB: BIOAF) CEO, Deborah Rathjen on the blood-brain barrier (Ep 44)


Manage episode 297177464 series 2907690
由Player FM以及我们的用户群所搜索的Jody Vance — 版权由出版商所拥有,而不是Player FM,音频直接从出版商的伺服器串流. 点击订阅按钮以查看Player FM更新,或粘贴收取点链接到其他播客应用程序里。

Deborah Rathjen, CEO of Bioasis Technologies (BTI.V) talks about the company's ground-breaking xB3 platform which allows therapeutic drugs to pass through the seemingly impenetrable blood-brain barrier, providing an effective treatment methodology for such neurological disorders as Alzheimer's disease, Lewy Body Dementia and Parkinson's. In short, Bioasis' final frontier solution could very well revolutionize medical science, potentially helping to heal the one billion people suffering from neurological disorders worldwide. Tune in!